Voicebrook Celebrates Record-Breaking Growth in Q4 of 2024 – PR.com

Roslyn
Heights,
NY,
February
10,
2025
–(PR.com)– Voicebrook,
the
industry
leader
in
reporting
solutions
for
anatomic
pathology,
is
thrilled
to
announce
a
historic
milestone:
Q4
of
2024
has
officially
become
the
best
quarter
in
the
company’s
more
than
20-year
history.
Fueled
by
extraordinary
demand
for
its
innovative
solutions,
Voicebrook
achieved
remarkable
growth
in
2024,
setting
the
stage
for
continued
success.

In
Q4
2024,
sales
soared
by
62%
compared
to
Q4
2023,
reaching
unprecedented
levels
and
reflecting
the
growing
demand
for
Voicebrook’s
pathology
solutions.

“This
record-breaking
quarter
is
a
testament
to
the
hard
work
of
our
team
and
the
trust
our
customers
place
in
us,”
said
E.
Bruce
Sopko,
VP
Sales
at
Voicebrook.
“We’re
not
only
achieving
new
heights,
but
also
building
lasting
partnerships
with
our
customers
as
they
embrace
our
solutions
to
drive
efficiency
and
success.”

The
impressive
results
cap
off
a
year
of
innovation
and
growth
for
Voicebrook,
as
it
continues
to
serve
roughly
500
client
sites
around
the
world.
The
company’s
VoiceOver
PRO
and
SynoptIQ
software
applications
allow
pathology
professionals
to
rapidly
and
accurately
create
pathology
reports.
VoiceOver
PRO
incorporates
speech
recognition,
digital
dictation,
customizable
templates,
CAP
eCP,
and
an
assortment
of
input
devices,
providing
direct
integration
with
the
user’s
Anatomic
Pathology
(AP)
system.
SynoptIQ
is
a
full-featured
eCP
solution
solely
focused
on
CAP
cancer
reporting,
at
a
budget-friendly
price
point.
Pathologists
receive
CAP
content
updates
from
Voicebrook
to
achieve
seamless
eCP
compliance.

“Our
strong
growth
reflects
the
increasing
demand
for
our
solutions
and
the
confidence
customers
have
in
our
ability
to
deliver
lasting
value,”
added
E.
Ross
Weinstein,
Voicebrook’s
CEO.
“This
isn’t
just
a
record-breaking
quarter—it’s
the
foundation
for
an
even
brighter
future.”

In
2024,
Voicebrook
became
the
first
and
only
provider
of
pathology
reporting
solutions
to
utilize
generative
AI
to
draft
diagnoses
in
cancer
case
reports,
improving
accuracy
and
efficiency.
By
the
end
of
2024,
the
company
unveiled
three
GenAI-powered
features
designed
to
streamline
workflows
and
make
the
reporting
process
more
efficient
for
pathologists,
technicians,
and
PAs.

Looking
ahead
to
2025
and
beyond,
the
company
remains
committed
to
driving
innovation,
expanding
its
impact,
and
delivering
exceptional
value
to
customers
worldwide.